Pfizer COVID-19 vaccine appointments are available to our patients. Sign up for Connect today to schedule your vaccination.

Multi-modal neuroimaging and cognitive assessment of females with multiple sclerosis across different stages of menopause

Clinical Trial Details

This project hopes to learn how menopause is impacting the bodies and lives of female multiple sclerosis (MS) patients to enable better management of the disease. We want to see how menopause affects cognition in females with MS compared to healthy females.

This study will compare menopause-related changes in brain structure, function, metabolism, and vasculature in females with MS versus healthy females. Additionally, we want to look at the relationship between imaging biomarkers and cognition across the three stages of menopause. An imaging biomarker is a biologic feature detectable in an image.

Participants in this study will receive cognitive testing (taking about 1.5 hours), a blood draw (taking about 10 minutes), and a non-contrast MRI scan of their head (taking about 1 hour).

Total study participation will take roughly 3 hours. The cognitive testing, blood draw, and MRI may take place on either on the same day or on separate dates depending on schedules.

Key Eligibility: 

Inclusion Criteria:

  1. Female between 45-60 years of age.
  2. Diagnosis of relapsing remittent multiple sclerosis or healthy control with no indications of multiple sclerosis

Exclusion Criteria

  1. Males of any age or females younger than 45 years of age or greater than 60 years of age.
  2. Clinically isolated syndrome and progressive disease evolution.
  3. Contraindications to MRI (i.e., metal in their body or claustrophobia), preexisting brain injury, neurological disease (other than MS).
  4. Psychiatric disease (including major depression/anxiety) or active depression symptoms.
  5. Pregnancy.
  6. Received hormone therapy before, during, or after menopause.

Detailed eligibility will be discussed when reaching out to the study team.

Study contact by location

Upper East Side - Manhattan


Riley Timken
(646) 962-6351

Primary Investigator(s)

Protocol ID(s)

Weill Cornell Medicine IRB #:



Open to Enrollment

Age Group